ALLMedicine™ Severe Acute Respiratory Syndrome Center

Nov 4th, 2021 - The messenger RNA vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) and the viral vector vaccine JNJ-78436735 (Janssen) have effectively prevented clinically significant disease caused by severe acute respiratory syndrome coronavirus 2 (...

May 18th, 2021 - Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar.

Dec 2nd, 2021 - In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, consultations and pregnancy monitoring examinations had to be reorganised urgently. In addition, women themselves may have postponed or cancelled their me...

Dec 2nd, 2021 - The first ever US Food and Drug Administration-approved messenger RNA vaccines are highly protective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1-3. However, the contribution of each dose to the generation of antibodies ag...

Dec 2nd, 2021 - To measure the psychological well-being of healthcare workers (HCWs) during this COVID-19 pandemic and examine the experiences of the subgroup of participants who were also HCWs during the 2003 SARS epidemic. Anonymous online survey adapted from a...

Nov 4th, 2021 - The messenger RNA vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) and the viral vector vaccine JNJ-78436735 (Janssen) have effectively prevented clinically significant disease caused by severe acute respiratory syndrome coronavirus 2 (...

May 18th, 2021 - Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar.

Sep 9th, 2021 - This technical report accompanies the recommendations of the American Academy of Pediatrics for the routine use of the influenza vaccine and antiviral medications in the prevention and treatment of influenza in children during the 2021-2022 season...

May 25th, 2021 - This guideline provides updated recommendations on the role of preprocedure testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in individuals undergoing endoscopy in the post-vaccination period and replaces the prior guideline...

Apr 20th, 2021 - To describe updates to pragmatic recommendations that were published during the first coronavirus disease 2019 (COVID-19) surge, including the current thinking about whether pregnancy worsens the severity of COVID-19. Although a majority of pregna...

Nov 4th, 2021 - The messenger RNA vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) and the viral vector vaccine JNJ-78436735 (Janssen) have effectively prevented clinically significant disease caused by severe acute respiratory syndrome coronavirus 2 (...

May 18th, 2021 - Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar.

Nov 25th, 2021 - PRIMARY OBJECTIVES: I. Characterize patient factors, such as pre-existing comorbidities, cancer type and treatment, and demographic factors, associated with short- and long-term outcomes of coronavirus 2019 (COVID-19), including symptoms, severity...

Nov 24th, 2021 - The aim of the COVID-19 vaccine clinical development program is to develop a safe and effective vaccine for the prevention of COVID-19. Currently, there is only limited availability of authorized/licensed vaccines for the prevention of coronavirus...

Nov 24th, 2021 - The aim of the COVID-19 vaccine clinical development program is to develop a safe and effective vaccine for the prevention of COVID-19. Ad26.COV2.S, a COVID-19 vaccine based on a human replication-incompetent Ad26 vector, constructed to encode the...

Nov 4th, 2021 - The messenger RNA vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) and the viral vector vaccine JNJ-78436735 (Janssen) have effectively prevented clinically significant disease caused by severe acute respiratory syndrome coronavirus 2 (...

May 18th, 2021 - Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections were assessed in a cohort of antibody-positive persons in Qatar.

Oct 15th, 2021 - As of September 30, 2021, there have been more than 231 million confirmed cases of COVID-19 and more than 4.7 million COVID-19–related deaths worldwide. Vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a crit...

Oct 6th, 2021 - Patrick I. Borgen, MD The rapid developments regarding coronavirus 2019 (COVID-19) have raised the question of how this virus could impact patients with cancer who are receiving immunosuppressive therapies. As such, multiple institutions, includ...

Sep 21st, 2021 - STUNG TRENG, Cambodia (Reuters) - Researchers are collecting samples from bats in northern Cambodia in a bid to understand the coronavirus pandemic, returning to a region where a very similar virus was found in the animals a decade ago. Two sample...